Sign In
Buy NKTX
$2.72
-0.190 (-6.53%)
At Close: Jun 03, 2026
3 Silent Tech Titans-in-the-Making: Invest Before They Skyrocket
06:30am, Thursday, 29'th Feb 2024
Among tech investments, the search for the next titan resembles a deep dive into the ocean for pearls. The periodic portfolio shifts toward solid tech contenders with high-yield potential as the digit
Nkarta to Participate in Upcoming Investor Conferences
08:01am, Wednesday, 28'th Feb 2024
SOUTH SAN FRANCISCO, Calif., Feb. 28, 2024 (GLOBE NEWSWIRE) -- Nkarta, Inc. (Nasdaq: NKTX), a biopharmaceutical company developing engineered natural killer (NK) cell therapies, today announced its pa
Last Call! 7 Small-Cap Stocks Ready to Explode in Value
04:19pm, Tuesday, 20'th Feb 2024
The article lists seven small-cap stocks for those looking for opportunities that promise exponential return potential. From innovative biotech firms to edgy technology providers, small-cap stocks are
3 Under-the-Radar Stocks Set to Soar 300% by 2026
09:32am, Thursday, 08'th Feb 2024
In the stock markets, where giants often steal the investment spotlight, hidden gems await discovery. Beyond the limelight lay under-the-radar stocks for 300% growth, teeming with potential and ready
3 Sleeper Stocks With Serious Potential to Make You a Millionaire
12:50pm, Tuesday, 06'th Feb 2024
Amidst the bustle of large tech giants taking up the artificial intelligence ( AI ) space and news headlines of leading pharmaceutical juggernauts marking key development milestones, many quality stoc
3 Once-in-a-Lifetime Biotech Stocks With Unprecedented Surge Potential
12:41pm, Monday, 05'th Feb 2024
The biotech sector is one of my favorite sectors since it is not only constantly growing and with companies that are always doing wonderful research, products, and solutions, but it is also a sector t
Unseen Giants: 3 Stocks Quietly Preparing for a 10X Surge
08:00am, Sunday, 04'th Feb 2024
Some stocks silently position themselves for monumental bursts. These companies, spanning the semiconductor, healthcare and biotechnology sectors, are emerging as unseen giants with the potential for
Penny Stocks To Buy Now? 4 To Watch Before 2024
10:11am, Tuesday, 19'th Dec 2023
As we enter 2024, investors wonder if it will be another volatile year for stocks. Maybe we see some stabilization after 2023's ups and downs; maybe not.
All You Need to Know About Nkarta, Inc. (NKTX) Rating Upgrade to Buy
01:32pm, Friday, 08'th Dec 2023
Nkarta, Inc. (NKTX) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Nkarta to Participate at Upcoming Investor Conferences
08:02am, Tuesday, 07'th Nov 2023
SOUTH SAN FRANCISCO, Calif., Nov. 07, 2023 (GLOBE NEWSWIRE) -- Nkarta, Inc. (Nasdaq: NKTX), a biopharmaceutical company developing engineered natural killer (NK) cell therapies, today announced its pa
Nkarta (NKTX) Rallies 112% as FDA Clears IND for Lupus Drug
12:03pm, Wednesday, 18'th Oct 2023
Nkarta (NKTX) rallies 112% on FDA nod to begin the clinical development of its investigational candidate, NKX019, for the treatment of lupus nephritis.
SOUTH SAN FRANCISCO, Calif., Oct. 16, 2023 (GLOBE NEWSWIRE) -- Nkarta, Inc. (Nasdaq: NKTX), a biopharmaceutical company developing engineered natural killer (NK) cell therapies, today announced that i
3 Promising Biotech Stocks That Will Make Early Investors Rich
03:07pm, Monday, 02'nd Oct 2023
For investment ideas that can potentially lead to life-changing gains, few sectors are as viable as biotech stocks to make you rich. Fundamentally, the biotechnology sector offers potential therapeuti
Nkarta to Participate at Upcoming Investor Conference
08:02am, Thursday, 03'rd Aug 2023
SOUTH SAN FRANCISCO, Calif., Aug. 03, 2023 (GLOBE NEWSWIRE) -- Nkarta, Inc. (Nasdaq: NKTX), a biopharmaceutical company developing engineered natural killer (NK) cell therapies, today announced its pa
3 Hidden Penny Stocks That Could Turn $100 into $10,000
06:30pm, Monday, 31'st Jul 2023
Investing in penny stocks can feel like finding needles in a haystack, and can certainly be an uphill battle for most investors. Different from investing in well-established businesses, you can't hold
